Biotech’s richest startup, Moderna Therapeutics, is losing its top attorney amid a legal fight that threatens its future profitability. His exit comes just two months after one of Moderna’s key partners aligned with its legal rival, casting further doubt on the company’s odds of prevailing in court.

The new developments — coming atop a string of departures of top executives — underline swirling questions over whether Moderna can follow through on its oft-repeated promise to upend the drug industry.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy